Pfizer’s Advanced Pharmaceutical Manufacturing (APM) is the world’s first advanced manufacturing solution, according to the company.
It allows the company to build, fabricate and distribute its products in a more cost-effective way than traditional manufacturing processes.
The company has been developing its technology since 2012, when it developed a proprietary technology that was used to develop a brand new drug.
Pfizer has been working with a number of pharmaceutical manufacturing companies and research labs to bring its technology to market.
The company has also partnered with medical device companies, which is expected to drive demand for the technology.
The process of manufacturing Pfizer drugs in the lab, which involves the manufacturing of the drug by injection or injectionable device, is called the “Pfizer-Fmea method.”
This is the same process that Pfizer uses to manufacture its products.
The process of making drugs in Pfizer-owned factories costs $5.6 billion annually, according the company, while the company estimates it would cost $9.4 billion to develop and manufacture a new drug from Pfizer.
The pharmaceutical industry has been using this process for decades, but it was only recently that it became a viable option.
The JHP technology is not available in the U.S. yet, but the company is working on a commercialized product.
The APM process was originally developed by the JMP Group, a company that is owned by Pfizer parent company AstraZeneca.
The new JHP manufacturing process is expected for commercial use by Pfizern in the second half of 2019.
The development of this new manufacturing technology was one of the first steps in the company’s quest to become a global leader in the pharmaceutical industry.
Pfizens APM was first launched in 2011.
The first manufacturing of a new pharmaceutical was completed in 2016.